Article

International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.

Department of Hematology, University Medical Center Utrecht, Utrecht, the Netherlands.
Journal of Clinical Oncology (Impact Factor: 17.88). 10/2010; 28(29):4521-30. DOI: 10.1200/JCO.2010.29.7929
Source: PubMed

ABSTRACT To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group.
In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized.
Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation.
New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials.

0 Bookmarks
 · 
122 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The treatment of multiple myeloma has undergone significant changes and has resulted in the achievement of molecular remissions, the prolongation of remission duration, and extended survival becoming realistic goals, with a cure being possible in a small but growing number of patients. In addition, nowadays it is possible to categorize patients more precisely into different risk groups, thus allowing the evaluation of therapies in different settings and enabling a better comparison of results across trials. Here, we review the evidence from clinical studies, which forms the basis for our recommendations for the management of patients with myeloma. Treatment approaches depend on "fitness," with chronological age still being an important discriminator for selecting therapy. In younger, fit patients, a short three drug-based induction treatment followed by autologous stem cell transplantation (ASCT) remains the preferred option. Consolidation and maintenance therapy are attractive strategies not yet approved by the European Medicines Agency, and a decision regarding post-ASCT therapy should only be made after detailed discussion of the pros and cons with the individual patient. Two- and three-drug combinations are recommended for patients not eligible for transplantation. Treatment should be administered for at least nine cycles, although different durations of initial therapy have only rarely been compared so far. Comorbidity and frailty should be thoroughly assessed in elderly patients, and treatment must be adapted to individual needs, carefully selecting appropriate drugs and doses. A substantial number of new drugs and novel drug classes in early clinical development have shown promising activity. Their introduction into clinical practice will most likely further improve treatment results.
    The Oncologist 07/2014; · 4.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Das Verständnis der Biologie hämatologischer Erkrankungen und die detaillierte Kenntnis der Signaltransduktion in normalen und malignen Zellen sowie die Zahl der bekannten zytogenetischen und molekularen Veränderungen nehmen rasant zu. Die Anwendung neuer zielgerichteter Therapieoptionen ist an eine komplexe morphologische, immunologische und genetische Diagnostik gebunden. Die klassischen Krankheitsentitäten werden diversifiziert. Neue Klassifikations- und Scoringsysteme bieten Grundlagen für risikoadaptierte und subgruppenspezifische Therapiestrategien.Der Beitrag stellt die aktuellen Möglichkeiten der Anwendung zielgerichteter Therapien bei malignen hämatologischen Erkrankungen mit zugelassenen Medikamenten und in klinischen Studien dar und zeigt Entwicklungslinien auf.Recherche und Auswertung von Literatur.Nach Einführung des CD20-Antikörpers Rituximab in die Therapie maligner B-Zell-Lymphome und von Imatinib in die Therapie der chronischen myeloischen Leukämie (CML) hat sich die Anwendung zielgerichteter Therapien in der Hämatologie rasant entwickelt. Die Kenntnis der krankheitsspezifischen Signaltransduktionswege ist von enormer Bedeutung für die Entwicklung geeigneter Therapien.
    Der Onkologe 01/2013; 19(10). · 0.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Consensus statements and clinical practice guidelines are widely available for enhancing the care of cancer patients. Despite subtle differences in their definition and purpose, these terms are often used interchangeably. We systematically assessed the methodological quality of consensus statements and clinical practice guidelines published in three commonly read, geographically diverse, cancer-specific journals. Methods Consensus statements and clinical practice guidelines published between January 2005 and September 2013 in Current Oncology, European Journal of Cancer and Journal of Clinical Oncology were evaluated. Each publication was assessed using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) rigour of development and editorial independence domains. For assessment of transparency of document development, 7 additional items were taken from the Institute of Medicine's standards for practice guidelines and the Journal of Clinical Oncology guidelines for authors of guidance documents.
    PLoS ONE 10/2014; · 3.53 Impact Factor